Normoglycemia may encompass two subpopulations with respect to vascular risk in non-obese Caucasian women

Laboratory Medicine

Volumn 36, Issue 1, 2005, Pages 35-40

  Behan, Kristina Jackson ^a   Amin, Raid W ^a  

^a UNIVERSITY OF WEST FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; URIC ACID;

ADULT; AGE; AGED; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; INFLAMMATION; LABORATORY TEST; LEUKOCYTE; NORMAL HUMAN; OBESITY; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL;

EID: 11344283567     PISSN: 00075027     EISSN: None     Source Type: Journal    
DOI: 10.1309/FYP50BGVPVLJ9YK4     Document Type: Article

References (39)

1. American Diabetes Organization Available at http://www.diabetes.org. Accessed on December 8, 2003.
2. American Diabetes Association position statement: Screening for diabetes. Diabetes Care. 2002;25:S21-S24.
3. Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. Diabetes Care. 1998;21:518-524.
4. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2002;25:S5-S20.
5. Diabetes control and complications trial/epidemiology of diabetes interventions and complications research group. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med. 2003;348:2294-2303.
6. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383-393.
7. Saydah SH, Loria CM, Eberharde MS, et al. Subclinical states of glucose intolerance and risk of death in the U.S. Diabetes Care. 2001;24:447-453.
8. Temelkova-Kurktschiev T, Koehler C, Leonhardt W, et al. Increased intimal-medial thickness in newly detected type 2 diabetes. Diabetes Care. 1999;22:333-338.
9. Coutino M, Gerstein H, Wang Y, et al. The relationship between glucose and incident cardiovascular events. Diabetes Care. 1999;22:233-240.
10. Expert Panel on Detection and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
11. Festa A, D'Agostino R, Howard G, et al. Chronic subclinical inflammation as part of the insulin resistance syndrome. Circulation. 2000;102:42-47.
12. Sakkinen PA, Wahl P, Cushman M, et al. Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. Am J Epidemiol. 2000;152:897-907.
13. Lempiainen P, Mykkanen L, Pyorala K, et al. Insulin resistance syndrome predicts coronary heart disease events in elderly nondiabetic men. Circulation. 1999;100:123-128.
14. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults. JAMA. 2002;287:356-359.
15. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003;26:3160-3167.
16. Bjornholt JV, Erikssen G, Aaser E, et al. Fasting blood glucose: An underestimated risk factor for cardiovascular death. Diabetes Care. 1999;22:45-49.
17. Park S, Barrett-Connor E, Wingard DL, et al. GHb is a better predictor of cardiovascular disease than fasring or postchallenge plasma glucose in women without diabetes. The Rancho Bernardo Study. Diabetes Care. 1996;19:450-456.
18. Friedewald WT, Levy RI, Frederikson DS. Estimation of the concentration of LDL choelsterol in plasma without the use of the preparative centrifuge. Clin Chem. 1972;18:499-502.
19. Grundy SM. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am J Cardiol. 1998;81:18B-25B.
20. Lakka H-M, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288:2709-2716.
21. St-Pierre J, Lemieux I, Vohl M-C, et al. Contribution of abdominal obesity and hypertriglyceridemia to impaired fasting glucose and coronary artery disease. Am J Cardiol. 2002;90:15-18.
22. Bo S, Cavallo-Perin P, Gentile L, et al. Hypouricemia and hyperuricemia in type 2 diabetes: Two different phenotypes. Eur J Clin Invest. 2001;31:318-321.
23. Temelkova-Kurktschiev T, Koehler C, Henkel E, et al. Leukocyte count and fibrinogen are associated with carotid and femoral Entima-media thickness in an at risk population for diabetes. Cardiovasc Res. 2002;56:277-283.
24. Kiechl S, Egger G, Mayr M, et al. Chronic infections and the risk of carotid atherosclerosis. Circulation. 2001;103:1064-1070.
25. Harris SB, Zinman B, Hanley A, et al. The impact of diabetes on cardiovascular risk factors and outcomes in a native Canadian population. Diabetes Res Clin Pract. 2002;55:165-173.
26. Hanley AJG, Stern MP, Williams K, et al. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease. Diabetes Care. 2002;25:1177-1184.
27. Abbasi F, Brown BW, Lamendola C, et al. Relationship between obesity, insulin resistance, and coronaty heart disease risk. J Am Coll Cardiol. 2002;40:937-943.
28. Mogul HR, Weinstein BI, Mogul DB, et al. Syndrome W: A new model of hyperinsulinemia, hypertension and midlife weight gain in healthy women with normal glucose tolerance. Heart Disease. 2002;4:78-85.
29. Temelkova-Kurktschiev T, Sieger G, Bergmann S, et al. Subclinical inflammation is strongly related to insulin resistance but not to impaired insulin secretion in a high risk population for diabetes. Metabolism. 2002;51:743-749.
30. Ridker P, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-979.
31. Koenig W, Sund M, Frohlich M, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men. Circulation. 1999;99:237-242.
32. Ross R. Atherosclerosis - An inflammatory disease. N Eng J Med. 1999;340:115-126.
33. Moro E, Alessandrini P, Zambon C, et al. Is glycation of low density lipoproteins in patients with Type 2 diabetes mellitus a LDL pre-oxidative condition? Diabet Med. 1999;16:663-9.
34. Lee W, Min W-K, Chim S, Jang S, Kim JQ, Lee DH, Park JY, Park H, Son JE. Low-density lipoprotein subclass and its correlating factors in diabetics. Clin Biochem 2003;36:657-661.
35. Vojdani A. A look at infectious agents as a possible causative factor in cardiovascular disease Part I. Lab Med. 2003;34:203-212.
36. Vojdani A. A look at infectious agents as a possible causative factor in cardiovascular disease Part II. Lab Med. 2003;34:288-292.
37. Vojdani A. A look at infectious agents as a possible causative factor in cardiovascular disease Part III. Lab Med. 2003;34:388-396.
38. Van Oostrom AJHHM, Sijmonsma TP, Verseyden C, et al. Postprandial recruitment of neutrophils may contribute to endothelial dysfunction. J Lipid Res. 2002;44:576-583.
39. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.